Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial
Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
TROP2 expression measured by QCS is a promising predictor of clinical outcomes in patients with mNSCLC
McVie-Veronesi Award Lecture “The quest to deliver a balance between the best care and Choosing Wisely”
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Cancer mutation prediction using artificial intelligence
ESMO 2024: Latest in EGFR mutated NSCLC
Understanding the use of PARPi combinations to treat patients with mCRPC
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Trastuzumab deruxtecan effective against brain metastases in HER2-positive breast cancer